Preveceutical Medical Inc · CSE:PREV
Preveceutical Medical — Investor Presentation (April 2026)
26 slides from Preveceutical Medical's investor presentation, April 2026
Slide 1: Sol-Gel Brain Delivery Platform for Parkinson's Disease
CORPORATE PRESENTATION SOL-GEL BRAIN DELIVERY PLATFORM FOR PARKINSON’S DISEASE April 2026 CSE: PREV OTCQB: PRVCF FSE: 18H
Slide 2: Disclaimer
DISCLAIMER This presentation and its appendices (together the “Presentation”) have been prepared and delivered by PreveCeutical® Medical Inc. (“PreveCeutical” or the “Company”) (CSE: PREV, OTCQB: PRVCF, FSE: 18H). The Presentation and its contents are strictly confidential and may not be reproduced
Slide 3: Corporate Overview
CORPORATE OVERVIEW Preventive health sciences company with corporate offices in Vancouver, Canada, and wholly-owned subsidiary in Brisbane, Australia. Leverage innovative science & technology to enhance natural products as novel targeted therapeutics in a diverse portfolio of R&D programs addressing
Slide 4: Sol-Gel Platform: Revolutionizing Drug Delivery to the Brain
SOL-GEL PLATFORM: REVOLUTIONIZING DRUG DELIVERY TO THE BRAIN The Sol-Gel platform: is an adaptable aqueous-based formulation employing FDA-approved excipients provides controlled and sustained delivery of therapeutics is amenable to various routes of administration, including intranasally for direct
Slide 5: How Does the Sol-Gel Work?
HOW DOES THE SOL-GEL WORK? It is a solution that is engineered to rapidly gel upon contact with mucosa Supports controlled and sustained release to and through the mucosa Compatible with active pharmaceutical ingredients (APIs) of diverse chemical nature such as siRNA, mRNA, DNA, antibodies (and the
Slide 6: Versatile Administration & Patented Technology
VERSATILE ADMINISTRATION & PATENTED TECHNOLOGY Multiple Routes Patented Amenable to nasal, buccal, Proprietary technology for throat, ear, topical, vaginal safe and effective delivery and rectal administration of diverse therapeutic entities Sol-Gel offers sustained delivery - from hours thru to day
Slide 7: Sol-Gel Delivery: Why Nose-to-Brain?
SOL-GEL DELIVERY WHY NOSE-TO-BRAIN? 01 02 03 04 Direct Drug Delivery to Brain Challenges with Oral Route BBB Permeability Leverage Olfactory Pathway Patient outcomes of CNS Rapid breakdown of Challenging to reach the Ideal pathway to deliver (central nervous system) enzymes in gut; incidences brain
Slide 8: Sol-Gel Platform Technology & Device
SOL-GEL PLATFORM TECHNOLOGY & DEVICE Conventional nasal sprays deliver Olfactory mucosa targeting, rapid sol- formulation throughout the nasal cavity, to-gel transition, muco-retention leading and are rapidly cleared… to sustained delivery • Anterior & posterior leakage • Exclusive olfactory targeti
Slide 9: Key Applications & Therapeutic Targets
KEY APPLICATIONS & THERAPEUTIC TARGETS “Sol-gel technology has certainly shown significant CNS Disorders promise in laboratory testing at this point. Eventually, Targets the central nervous system for neurological and I would like to see this proprietary technology be psychiatric conditions e.g. Par
Slide 10: Functional Advantages
FUNCTIONAL ADVANTAGES ✓Innovative delivery system ✓Micro-dosing to potentially reduce or eliminate side effects ✓Sustained release; potentially for bi-weekly dosing ✓Precision delivery; greater bioavailability ✓Significant potential across a broad range of CNS disorders ✓Amenable to nasal, buccal, t
Slide 11: Parkinson's Disease
PARKINSON’S DISEASE What is Parkinson’s Disease? A progressive neurological disorder characterized by the degeneration of dopamine-producing neurons within the brain, leading to various motor and non-motor symptoms. While its primary impact is on movement, it also affects mental health, sleep patter
Slide 12: Parkinson's Disease – Market Size
PARKINSON’S DISEASE – MARKET SIZE In 2024, it was estimated that 10 million people globally were living with Parkinson’s disease (citation). Parkinson’s disease will affect over 25 million people by 2050 (citation). Parkinson’s disease treatment market to reach US$11.66 billion by 2030 (citation). L
Slide 13: Parkinson's Disease Current Treatment
Parkinson’s Disease Current Treatment Effective management of symptoms in Parkinson’s disease relies on steady state brain concentrations of L-Dopa. However, current oral L-Dopa treatment results in fluctuations in brain drug concentration, which contribute to the side effect profile. Why does L-Dop
Slide 14: Parkinson's Disease Innovative Therapy with L-Dopa Sol-gel Nasal Spray
Parkinson’s Disease Innovative Therapy with L-Dopa Sol-gel Nasal Spray Key features: • Achieves and maintains steady state drug concentration in whole brain, within minutes • Sustained L-Dopa release profile from sol-gel avoiding peak-&-valley fluctuations • Supports extended dosing regimen, with su
Slide 15: Direct-to-brain 'dopamine' delivery
Direct-to-brain ‘dopamine’ delivery… • Currently, the endogenous neurotransmitter dopamine is not used in the treatment of Parkinson's disease as it cannot cross the blood-brain barrier and is rapidly metabolized in the periphery. • Dopamine is a promising candidate for sol-gel mediated brain delive
Slide 16: PreveCeutical Team
PREVECEUTICAL TEAM Stephen Van Deventer Mak Jawadekar PhD - Chairman and Chief Executive Officer – President, Chief Science Officer and Director Mr. Van Deventer is an experienced businessman and Dr. Jawadekar completed his Ph.D. in Pharmaceutics at the corporate director. Specializing in internatio
Slide 17: PreveCeutical Team
PREVECEUTICAL TEAM Kathy Rokita CPA C. Evan Ballantyne – Director – Director Ms. Rokita is a finance, operations, and strategy-focused Mr. Ballantyne has extensive executive leadership experience and executive having extensive experience with large medical groups. has spent the last 20 years as a pu
Slide 18: PreveCeutical Team
PREVECEUTICAL TEAM Raj Pruthi, MD, MHA, FACS Harry Parekh PhD, BSc Hons I - Director - Chief Research Officer Dr. Pruthi is a distinguished physician-scientist, executive leader Based at the University of Queensland’s (UQ) Pharmacy and board-level strategist with over 20 years of experience Australi
Slide 19: PreveCeutical Team
PREVECEUTICAL TEAM Francis Tavares, PhD Kamal Albarazanji – Chief Technology Officer - Director of Research Dr. Tavares has extensive experience in the preclinical Based at the University of Queensland’s (UQ) Pharmacy development of small molecule inhibitors in various target Australia Centre of Exc
Slide 20: PreveCeutical Team
PREVECEUTICAL TEAM Sydney Cole – Executive Assistant & Office Manager Ms. Cole has held Administration Support and trainer roles within the Hospitality Industry for seven years. Ms. Cole has also worked for a Venture Capital company for seven years as an executive assistant and office manager. From
Slide 21: PreveCeutical Australia Team
PREVECEUTICAL AUSTRALIA TEAM PreveCeutical® has established a wholly-owned subsidiary in Brisbane, Queensland, Australia, to bolster their research and development interests. The Australian team, which will be led by Stephen Van Deventer, the Chief Executive Officer, will work closely with Dr. Harry
Slide 22: Strategic Advisors/Collaborators
STRATEGIC ADVISORS/COLLABORATORS Dr. Ajit Shetty Aditya Bahl Dr. Shetty has extensive pharmaceutical experience Mr. Bahl brings over 20 years of experience in leading commercial and supply chain operations pharmaceutical marketing and clinical as well as significant educational background developmen
Slide 23: Research Collaborators
RESEARCH COLLABORATORS Dr. Bryan Jones Stephen Glover Dr. Jones has more than 30 years of experience with Mr. Glover joins PreveCeutical as a Corporate biotech and specialty pharmaceutical companies Advisor, bringing multifaceted experience in Fortune with roles in product and business development.
Slide 24: Research Collaborators
RESEARCH COLLABORATORS Dr. Deepak Sampath Dr. Sampath will serve as a Corporate Advisor for PreveCeutical. He is the Senior VP, Head of Research at Ultragenyx, with previous experience at Pfizer and Genetech, along with several patents in the treatment of cancers. He has extensive experience in smal
Slide 25: Key Partners
KEY PARTNERS THE UNIVERSITY DuM GB ovouesstann [B) | Bevoun griffith nA ac TN IP Amplified RAS
Slide 26: For Further Info
FOR Stephen Van Deventer info@preveceutical.com FURTHER Investor Relations INFO ir@preveceutical.com CONTACT 1 (604) 416-7777
PreveCeutical Medical — Investor Presentation (April 2026) on 6ix